Skip to main content
Clinical Trials/NCT06090149
NCT06090149
Recruiting
N/A

Telemedical Assistance in Automatic Titration of Oxygen for Intensive Care Patients

Pauls Stradins Clinical University Hospital1 site in 1 country30 target enrollmentMarch 1, 2023

Overview

Phase
N/A
Intervention
Not specified
Conditions
Obesity Hypoventilation Syndrome (OHS)
Sponsor
Pauls Stradins Clinical University Hospital
Enrollment
30
Locations
1
Primary Endpoint
Respiratory rate (RR)
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

The goal of this clinical trial is to clinically validate a system for the monitoring of patients' respiratory function and automated oxygen treatment proposal using non-invasive ventilation devices in the treatment of intensive care patients with acute or chronic lung diseases exacerbations. Participants clinical parameters will be monitored and samples will be sent to a clinical laboratory for analysis (arterial blood pressure, heart rate, and respiratory rate will be continuously recorded, and FeO2 and CO2 will be measured with the help of an additional sensor).

Detailed Description

This prospective experimental study is conducted in Pauls Stradins Clinical University Hospital (PSCUH) and Sleep Disease Center in Riga, Latvia. The study includes patients with respiratory failure and hypoxemia to whom NIV is indicated. Participants clinical parameters are monitored and samples will be sent to a clinical laboratory for analysis. Initial ventilation parameters will be defined by the clinician who performs the experiment. During the validation phase, the investigators will obtain clinicians' final decision on the changes of the ventilation system parameters and compare it to our module proposal. That way it would be possible to estimate if the system is ready for the next step - fully automated closed-loop ventilation system development.

Registry
clinicaltrials.gov
Start Date
March 1, 2023
End Date
November 30, 2023
Last Updated
2 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
Pauls Stradins Clinical University Hospital
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • signed informed consent to participate in the study;
  • aged over 18 years;
  • patients hospitalized with acute respiratory failure (indication to NIV therapy) with restrictive or obstructive lung disease

Exclusion Criteria

  • refusal to participate further in the study;
  • age under 18 years;
  • pregnancy;
  • the patient is contraindicated for non-invasive lung ventilation
  • during the study, the patients condition worsens in such a way that an active one is required medical intervention or continuation of the study may worsen the patients condition;
  • complications related to NIV therapy or claustrophobia;
  • chronic obstructive pulmonary disease and obstructive sleep apnea without documented hypoxemia (Sp02 and Sa02 \> 94%).

Outcomes

Primary Outcomes

Respiratory rate (RR)

Time Frame: 11 months

Evaluation will include the difference in the respiratory rate (xmin) measures pre-interventionally and during the intervention.

Apnea-Hypopnea Index (AHI)

Time Frame: 11 months

The change in the Apnea-Hypopnea Index (AHI) within oxygen titration will be measured pre-interventionally and during the intervention.

Transcutaneous CO2 partial pressure (tcCO2)

Time Frame: 11 months

The change in transcutaneous CO2 partial pressure (mmHg) within oxygen titration and the time spent within an acceptable CO2-interval measured pre-interventionally and during the intervention.

Blood Oxygen Saturation (SpO2)

Time Frame: 11 months

Evaluation will include the difference in blood Oxygen Saturation (SpO2%) pre-interventionally and during the intervention.

Upper airway Carbon dioxide levels (CO2)

Time Frame: 11 months

The change in CO2 (mmHg) within oxygen titration will be measured pre-interventionally and during the intervention.

Blood pressure (TA)

Time Frame: 11 months

Evaluation will include the difference in the blood pressure (mmHg) measures pre-interventionally and during the intervention.

Heart rate (HR),

Time Frame: 11 months

Evaluation will include the difference in the heart rate (xmin) pre-interventionally and during the intervention.

Secondary Outcomes

  • adverse events description(11 months)

Study Sites (1)

Loading locations...

Similar Trials